Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How do you approach treatment for a patient with T2N0, ER+/PR+, HER2 negative breast cancer with planned TC treatment following a hypersensitivity reaction?
Related Questions
What are your top takeaways from SABCS 2023?
Would you treat a patient with cT2 ER+/HER2+ breast cancer with neoadjuvant HER2 directed therapy if HER2 positivity is group 3?
Would you offer adjuvant endocrine therapy to a male with ER+ DCIS?
How do you approach a breast cancer patient with outside pathology returning as HER2 positive on FISH but internal pathology review showing conflicting results and HER2 negative on FISH on same sample?
What endocrine therapy would you recommend to a premenopausal female with early stage HR+ Breast cancer who is transitioning from female to male and currently on testosterone?
How would you approach adjuvant therapy for large (≥4 cm), node negative, HR+, HER2- breast cancer in an elderly woman with comorbidities including neuropathy?
How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?
Would you give adjuvant chemotherapy to a premenopausal female who underwent bilateral mastectomies for ER+ pT2N1 disease, grade 1, with low oncotype (5)?
